Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Peng Chen

5PUBLICATIONS

5CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Econometric and statistical methods

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (5)

Sort by Publication Date:

|Oct 29, 2025

Adagrasib in the treatment of KRAS<sup>G12C</sup>-mutated non-small cell lung cancer: a cost-effectiveness analysis.

Gengwei Huo, Ying Song, Shenge Liu

|May 13, 2024

Entrectinib as first-line <i>vs.</i> second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis.

Gengwei Huo, Ying Song, Xiongwen Chen

|Apr 12, 2024

Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.

Gengwei Huo, Ying Song, Peng Chen

|Apr 12, 2024

Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer.

Gengwei Huo, Ying Song, Peng Chen

|Feb 08, 2024

Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer.

Gengwei Huo, Wenjie Liu, Peng Chen

Pageof 1

Frequent Collaborators

5 joint publications

Gengwei Huo

3 joint publications

Ying Song

1 joint publications

Wenjie Liu

1 joint publications

Xiongwen Chen

1 joint publications

Xiaoning He

Frequent Collaborators

5 joint publications

Gengwei Huo

3 joint publications

Ying Song

1 joint publications

Wenjie Liu

1 joint publications

Xiongwen Chen

Top Related Videos

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on : Jul 21, 2018

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on : Sep 12, 2019

See more related videos

Top Related Videos

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on : Jul 21, 2018

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on : Sep 12, 2019

See more related videos